Larry L. Wood - 11 May 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
Global President TAVR & Surg
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
11 May 2023
Net transactions value
$0
Form type
4
Filing time
15 May 2023, 18:26:54 UTC
Previous filing
09 May 2023
Next filing
24 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Award $0 +7,775 +3.8% $0.000000 213,794 11 May 2023 Direct F1, F2
holding EW Common Stock 496 11 May 2023 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Award $0 +65,700 $0.000000 65,700 11 May 2023 Common Stock 65,700 $88.78 Direct F3
transaction EW Performance Rights Award $0 +9,725 $0.000000 9,725 11 May 2023 Common Stock 9,725 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted stock units were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
F2 Reflects shares transferred to the reporting person's ex-spouse pursuant to a divorce judgement. The securities owned by the ex-spouse are not beneficially owned by the reporting person.
F3 These options were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.
F4 Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.